NASDAQ · ADGM
Healthcare · Medical - Devices
$0.14
Down-$0.00 (-2.20%)
Updated Oct 7, 2026, 6:02 AM
SID Score
2.7/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · ADGM
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
ADGM closed at $0.14 after 21 trading sessions, down 77.28% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $0.138 | $0.1492 | $0.1303 | $0.138 | 1.56M |
| Oct 5, 2026 | $0.153 | $0.154 | $0.1375 | $0.1411 | 1.63M |
| Oct 2, 2026 | $0.1579 | $0.1597 | $0.149 | $0.1531 | 1.61M |
| Oct 1, 2026 | $0.156 | $0.179 | $0.15 | $0.156 | 7.73M |
| Sep 30, 2026 | $0.147 | $0.16 | $0.14 | $0.153 | 1.23M |
| Sep 29, 2026 | $0.177 | $0.177 | $0.1201 | $0.144 | 2.23M |
| Sep 28, 2026 | $0.1974 | $0.20 | $0.1618 | $0.1707 | 1.88M |
| Sep 25, 2026 | $0.216 | $0.22 | $0.185 | $0.195 | 2.09M |
| Sep 24, 2026 | $0.2102 | $0.2165 | $0.1755 | $0.21 | 5.85M |
| Sep 23, 2026 | $0.333 | $0.3529 | $0.2116 | $0.228 | 36.57M |
| Sep 22, 2026 | $0.501 | $0.5151 | $0.4402 | $0.4855 | 153.83K |
| Sep 21, 2026 | $0.5199 | $0.5199 | $0.4607 | $0.503 | 128.46K |
| Sep 18, 2026 | $0.506 | $0.5173 | $0.4811 | $0.4825 | 97.11K |
| Sep 17, 2026 | $0.5001 | $0.5226 | $0.4901 | $0.52 | 85.29K |
| Sep 16, 2026 | $0.488 | $0.5204 | $0.4601 | $0.499 | 185.52K |
| Sep 15, 2026 | $0.455 | $0.4997 | $0.431 | $0.4621 | 313.04K |
| Sep 14, 2026 | $0.561 | $0.60 | $0.4505 | $0.4505 | 471.53K |
| Sep 11, 2026 | $0.5601 | $0.61 | $0.5601 | $0.561 | 27.2K |
| Sep 10, 2026 | $0.59 | $0.6203 | $0.5718 | $0.58 | 100.76K |
| Sep 9, 2026 | $0.595 | $0.6398 | $0.5802 | $0.605 | 69.24K |
| Sep 8, 2026 | $0.579 | $0.6398 | $0.55 | $0.6075 | 180.6K |
The latest Smart Investors Daily articles mentioning ADGM.
Company
Market Activity
Research & News
ADGM research
Company profile and research snapshot.
Adagio Medical Holdings Inc is an innovator in catheter ablation technologies for the treatment of cardiac arrhythmias. The company focuses on developing cryoablation technologies that create contiguous, transmural lesions to treat cardiac arrhythmias, including paroxysmal and persistent atrial fibrillation, atrial flutter, and ventricular tachycardia.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 3, 2026 | LUCID CAPITAL MARKETS | Buy | — |
| Apr 14, 2026 | Piper Sandler | Overweight | — |
| Dec 2, 2025 | Lake Street | Buy | — |
No generated briefing is available yet.
Benzinga · Sep 30, 2026
Gainers Monte Rosa Therapeutics (NASDAQ:GLUE) stock rose 9.7% to $13.09 during Wednesday's after-market session. The company's market cap stands at $1.0 billion. Filana Therapeutics (NASDAQ:FLNA) shares rose
Benzinga · Sep 23, 2026
U.S. stocks fell Wednesday, led by a 1.1% Nasdaq drop. Cintas beat estimates and raised guidance; oil gained while gold, silver and copper declined.
Yahoo · Sep 23, 2026
LAGUNA HILLS, Calif., September 23, 2026--Adagio Medical Holdings, Inc. (Nasdaq: ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that its Board of Directors has completed a comprehensive review of the Company's business, programs, resources and capabilities and has initiated a formal process to explore strategic alternatives focused on maximizing shareholder value. In connection with this decision,
Benzinga · Sep 23, 2026
U.S. stocks fell Wednesday; General Mills beat estimates, energy rose, utilities declined, while oil gained and gold dropped.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ADGM.
